Hemay005 for Behçet's disease mouth sores
Treatments studied
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have at least 2 mouth sores from Behçet's disease and need medication that works throughout your body (not just creams).
- You cannot have active Behçet's in major organs like the lungs, blood vessels, brain, or gut (for example, bleeding ulcers or aneurysms).
- You must not have taken certain immune-suppressing drugs recently (like colchicine, methotrexate, or biologics) or ever taken apremilast.
- You cannot have other serious autoimmune diseases, active infections, or certain lab abnormalities (like low blood counts or kidney/liver issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the symptoms, lab results, and treatments for people with Behçet's disease. It may help doctors better understand and manage the condition.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
This trial studies lenalidomide to treat frequent, ongoing mouth ulcers caused by mucosal Behçet’s syndrome. It’s meant for people whose mouth sores keep coming back despite standard treatments like steroid medicines and other immune-suppressing drugs.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This trial tests an experimental pill, HSK44459, for people with Behçet's disease who have frequent mouth ulcers. It aims to see if the drug can safely reduce ulcer episodes and improve symptoms.
Hear when a new Behçet's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.